A Phase 3 cardiovascular outcomes trial assessing Plozasiran in patients with mixed hyperlipidemia
Latest Information Update: 27 Jun 2024
Price :
$35 *
At a glance
- Drugs Plozasiran (Primary)
- Indications Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms CAPITAN
- 27 Jun 2024 New trial record